AngioDynamics (NASDAQ:ANGO) Stock Rating Reaffirmed as “Buy” by Canaccord Genuity Group

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating reissued by Canaccord Genuity Group in a research report issued on Friday, Benzinga reports. They currently have a $20.00 target price on the medical instruments supplier’s stock. Canaccord Genuity Group’s price target suggests a potential upside of 72.04% from the company’s previous close.

A number of other equities analysts have also commented on the stock. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright raised their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, AngioDynamics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

AngioDynamics Price Performance

NASDAQ:ANGO traded up $0.40 on Friday, reaching $11.63. 1,573,168 shares of the company’s stock were exchanged, compared to its average volume of 502,886. The firm has a market cap of $488.83 million, a price-to-earnings ratio of -13.36 and a beta of 0.30. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29. The stock has a fifty day simple moving average of $15.39 and a 200-day simple moving average of $13.11.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts predict that AngioDynamics will post -0.25 EPS for the current year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds have recently bought and sold shares of ANGO. BlackRock Inc. purchased a new position in shares of AngioDynamics during the second quarter worth approximately $49,480,000. Weber Capital Management LLC ADV purchased a new position in shares of AngioDynamics during the second quarter worth approximately $17,649,392. Paradigm Capital Management Inc. NY purchased a new position in shares of AngioDynamics during the second quarter worth approximately $8,732,000. Western Standard LLC purchased a new position in shares of AngioDynamics during the second quarter worth approximately $5,037,000. Finally, Bank of America Corp DE raised its stake in shares of AngioDynamics by 262.7% during the first quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock worth $5,726,000 after acquiring an additional 364,763 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported adjusted EPS of a $0.04 loss, beating the consensus estimate of a $0.11 loss, while revenue reached approximately $80.9 million versus expectations of $80.5 million. Revenue increased 6.9% year over year, and gross margin expanded by 410 basis points to 59.4%. ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
• Positive Sentiment: Growth was strongest in the Med Tech segment, where sales rose 13.2%. Auryon revenue increased 14.7% to $18.9 million and NanoKnife revenue climbed 29% to $8.3 million, supporting the company’s growth strategy. Fiscal Year 2027 First Quarter Financial Results
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and maintained a $20 price target, implying substantial potential upside from recent trading levels. AngioDynamics Stock Is Falling Thursday: What’s Going On?
• Neutral Sentiment: Management reiterated fiscal 2027 revenue guidance of $336 million to $341 million and adjusted EPS guidance of a $0.29 to $0.24 loss, broadly in line with analyst expectations. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia, a potential longer-term catalyst. AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President and CEO
• Negative Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The leadership change may be weighing on sentiment because it introduces execution uncertainty even as the company transitions to a new chief executive. Appointment of Eric Honroth as President and Chief Executive Officer
• Negative Sentiment: AngioDynamics remains unprofitable, reporting a GAAP net loss of approximately $7.1 million, or $0.17 per share, and used $15.3 million in operating cash during the quarter. The stock’s decline on unusually heavy volume suggests investors focused more on profitability, cash burn and the CEO transition than on the earnings beat.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.